CURIS INC (CRIS)

US2312693094 - Common Stock

10.87  0 (0%)

Fundamental Rating

3

Taking everything into account, CRIS scores 3 out of 10 in our fundamental rating. CRIS was compared to 592 industry peers in the Biotechnology industry. While CRIS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CRIS is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

CRIS had negative earnings in the past year.
CRIS had a negative operating cash flow in the past year.
In the past 5 years CRIS always reported negative net income.
CRIS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -61.35%, CRIS is not doing good in the industry: 61.05% of the companies in the same industry are doing better.
The Return On Equity of CRIS (-241.04%) is worse than 72.62% of its industry peers.
Industry RankSector Rank
ROA -61.35%
ROE -241.04%
ROIC N/A
ROA(3y)-47.14%
ROA(5y)-49.53%
ROE(3y)-137.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CRIS has a better Gross Margin (97.77%) than 97.62% of its industry peers.
In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
CRIS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y0.68%

6

2. Health

2.1 Basic Checks

CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRIS has been increased compared to 1 year ago.
CRIS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -22.21, we must say that CRIS is in the distress zone and has some risk of bankruptcy.
CRIS has a Altman-Z score of -22.21. This is amonst the worse of the industry: CRIS underperforms 89.63% of its industry peers.
There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.21
ROIC/WACCN/A
WACC8.98%

2.3 Liquidity

A Current Ratio of 4.51 indicates that CRIS has no problem at all paying its short term obligations.
CRIS has a Current ratio (4.51) which is in line with its industry peers.
A Quick Ratio of 4.51 indicates that CRIS has no problem at all paying its short term obligations.
CRIS has a Quick ratio (4.51) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.51
Quick Ratio 4.51

4

3. Growth

3.1 Past

CRIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.56%, which is quite impressive.
CRIS shows a decrease in Revenue. In the last year, the revenue decreased by -1.42%.
CRIS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.79% yearly.
EPS 1Y (TTM)26.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.42%
Revenue 1Y (TTM)-1.42%
Revenue growth 3Y-2.58%
Revenue growth 5Y-0.79%
Revenue growth Q2Q-6.71%

3.2 Future

CRIS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.35% yearly.
CRIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.93% yearly.
EPS Next Y34.96%
EPS Next 2Y20.82%
EPS Next 3Y11.46%
EPS Next 5Y13.35%
Revenue Next Year0.27%
Revenue Next 2Y2.17%
Revenue Next 3Y8.44%
Revenue Next 5Y50.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.82%
EPS Next 3Y11.46%

0

5. Dividend

5.1 Amount

CRIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CURIS INC

NASDAQ:CRIS (3/28/2024, 8:03:29 PM)

10.87

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap64.02M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.35%
ROE -241.04%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 97.77%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.51
Quick Ratio 4.51
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.42%
Revenue growth 3Y-2.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y